Trials / Completed
CompletedNCT04551534
A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of DNL201 in Healthy Volunteers
A First-In-Human Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Single and Multiple Ascending Oral Doses of DNL201 in Healthy Subjects
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 122 (actual)
- Sponsor
- Denali Therapeutics Inc. · Industry
- Sex
- All
- Age
- 18 Years – 75 Years
- Healthy volunteers
- Accepted
Summary
This is a Phase 1, randomized, double-blind, placebo-controlled, single- and multiple-ascending oral dose study conducted in three parts.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | DNL201 | Oral dose(s) |
| DRUG | Placebo | Oral dose(s) |
Timeline
- Start date
- 2017-06-01
- Primary completion
- 2018-08-08
- Completion
- 2018-08-08
- First posted
- 2020-09-16
- Last updated
- 2020-09-16
Locations
1 site across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT04551534. Inclusion in this directory is not an endorsement.